Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi®
MONTREAL and LUGANO, Switzerland, May 12, 2022 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, and Helsinn Healthcare SA (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track record of commercial execution, today announced that Knight, through one of its wholly-owned […]
Knight to Present at the 2022 RBC Capital Markets Global Healthcare Conference in New York City
MONTREAL, May 11, 2022 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022 at 8:30 am ET at […]
Knight Therapeutics Inc. announces voting results from the Annual Meeting
MONTREAL, May 11, 2022 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Corporation”) a leading pan-American (ex-US) specialty pharmaceutical company, announced today the voting results from the Annual Meeting of the Shareholders held virtually in Montreal, Quebec (“Meeting”). Election of Directors Each director nominee listed in the Management Information Circular dated April 11, 2022 (“Circular”) […]
Notice of Knight Therapeutics’ First Quarter 2022 Results Conference Call
MONTREAL, May 05, 2022 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2022 financial results on Thursday, May 12, 2022 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate […]
Knight to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
MONTREAL, April 25, 2022 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2022 at 10:30 a.m. ET at the […]
Knight Therapeutics Inc. places on The Globe and Mail’s third-annual Women Lead Here benchmark of executive gender diversity
MONTREAL, March 25, 2022 — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it has been recognized in The Globe and Mail’s 2022 Report on Business Women Lead Here list. This annual editorial benchmark identifies best-in-class executive gender diversity in corporate Canada. Established in 2020 by Report on Business magazine, […]
Knight Therapeutics Reports Fourth Quarter and Year-End 2021 Results and Provides 2022 Revenue Guidance
MONTREAL, March 24, 2022 — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2021. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. […]
Notice of Knight Therapeutics’ Fourth Quarter and Year End 2021 Results Conference Call
MONTREAL, March 17, 2022 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2021 financial results on Thursday, March 24, 2022 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested […]
Knight Therapeutics Inc. Announces Approval of Halaven® in Colombia
MONTREAL, Jan. 06, 2022 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) announced today that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Halaven® (eribulin) injection. Halaven® (eribulin) injection is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer which has continued to spread after at […]
Knight Therapeutics Inc. Announces Approval of Lenvima® in Colombia
MONTREAL, Jan. 04, 2022 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) announced today that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Lenvima® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor developed by Eisai, for the treatment of radioiodine refractory differentiated thyroid cancer (RR-DTC) and unresectable hepatocellular carcinoma (u-HCC). […]
